The stock of Verastem Inc (VSTM) has gone down by -19.15% for the week, with a -39.04% drop in the past month and a -33.72% drop in the past quarter. The volatility ratio for the week is 2.42%, and the volatility levels for the past 30 days are 5.94% for VSTM.. The simple moving average for the past 20 days is -25.27% for VSTM’s stock, with a -12.22% simple moving average for the past 200 days.
Is It Worth Investing in Verastem Inc (NASDAQ: VSTM) Right Now?
Moreover, the 36-month beta value for VSTM is 0.83. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VSTM is 48.88M and currently, short sellers hold a 26.96% of that float. On June 25, 2025, VSTM’s average trading volume was 1.79M shares.
VSTM) stock’s latest price update
Verastem Inc (NASDAQ: VSTM)’s stock price has gone rise by 2535440 in comparison to its previous close of 4.62, however, the company has experienced a -19.15% decrease in its stock price over the last five trading days. businesswire.com reported 2025-06-24 that BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in VS-7375-101, the U.S. Phase 1/2a clinical trial evaluating VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, in patients with advanced KRAS G12D mutant solid tumors. “We continue to make strong progress against our strategic priorities and key mil.
Analysts’ Opinion of VSTM
Many brokerage firms have already submitted their reports for VSTM stocks, with Jefferies repeating the rating for VSTM by listing it as a “Buy.” The predicted price for VSTM in the upcoming period, according to Jefferies is $15 based on the research report published on April 10, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VSTM reach a price target of $10, previously predicting the price at $7. The rating they have provided for VSTM stocks is “Buy” according to the report published on March 24th, 2025.
BTIG Research gave a rating of “Buy” to VSTM, setting the target price at $20 in the report published on December 31st of the previous year.
VSTM Trading at -30.82% from the 50-Day Moving Average
After a stumble in the market that brought VSTM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.89% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VSTM starting from Paterson Dan, who sale 17,808 shares at the price of $5.13 back on Jun 20 ’25. After this action, Paterson Dan now owns 443,839 shares of Verastem Inc, valued at $91,355 using the latest closing price.
Calkins Daniel, the Chief Financial Officer of Verastem Inc, sale 4,110 shares at $5.13 during a trade that took place back on Jun 20 ’25, which means that Calkins Daniel is holding 109,945 shares at $21,084 based on the most recent closing price.
Stock Fundamentals for VSTM
Current profitability levels for the company are sitting at:
- -5461.29 for the present operating margin
- 0.25 for the gross margin
The net margin for Verastem Inc stands at -6203.21. The total capital return value is set at -1.36. Equity return is now at value -2159.50, with -116.66 for asset returns.
Based on Verastem Inc (VSTM), the company’s capital structure generated 1.8 points at debt to capital in total, while cash flow to debt ratio is standing at -1.58. The debt to equity ratio resting at -2.24. The interest coverage ratio of the stock is -40.45.
Currently, EBITDA for the company is -125.86 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of 8573.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.50.
Conclusion
To wrap up, the performance of Verastem Inc (VSTM) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
